Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.

被引：1
|
作者：
Gilcrease, Glynn Weldon
Weis, John R.
Jones, Kimberly
Davis, Thaylon
Mitchell, Marlene
Davidson, Cynthia
Sharma, Sunil
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
    Park, S.
    Chapuis, N.
    St Marcoux, F.
    Recher, C.
    Prebet, T.
    Chevallier, P.
    Cahn, J-Y
    Leguay, T.
    Bories, P.
    Witz, F.
    Lamy, T.
    Mayeux, P.
    Lacombe, C.
    Demur, C.
    Tamburini, J.
    Merlat, A.
    Delepine, R.
    Vey, N.
    Dreyfus, F.
    Bene, M. C.
    Ifrah, N.
    Bouscary, D.
    LEUKEMIA, 2013, 27 (07) : 1479 - 1486
  • [32] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [33] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [34] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [35] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [36] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies.
    Yee, KWL
    Wierda, W
    O'Brien, S
    Thomas, D
    Kurzrock, R
    Fayad, LE
    Hagemeister, FB
    Cortes, J
    Prestifilippo, K
    Szatrowski, TP
    Kantarjian, HM
    Giles, FJ
    BLOOD, 2004, 104 (11) : 287B - 287B
  • [37] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [38] Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, UJ
    Mayer, S
    Achterrath, W
    Hense, J
    Omidi, S
    Frings, S
    Harstrick, A
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [39] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    H Y Sheikh
    J W Valle
    K Palmer
    A Sjursen
    O Craven
    G Wilson
    R Swindell
    M P Saunders
    British Journal of Cancer, 2007, 96 : 38 - 43
  • [40] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Craven, O.
    Wilson, G.
    Swindell, R.
    Saunders, M. P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 38 - 43
12345